GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
about
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccineEfficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of ageAdjuvants: Classification, Modus Operandi, and LicensingVaccine adjuvants as potential cancer immunotherapeuticsCurrent status of human papillomavirus vaccinesSafety assessment of adjuvanted vaccines: Methodological considerationsPotentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionProtection of young children from influenza through universal vaccination.Adjuvants for peptide-based cancer vaccinesRecent advances of vaccine adjuvants for infectious diseasesThe March Toward Malaria VaccinesHuman papilloma virus in oral cancerImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsSeasonal influenza vaccination and technologies.A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza virusesInfluenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak.New adjuvanted vaccines in pregnancy: what is known about their safety?Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled TrialEffect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccineCationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.Design and synthesis of potent Quillaja saponin vaccine adjuvantsDendritic Cell Dysfunction in Patients with End-stage Renal DiseaseBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerSafety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studiesAssessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient careAS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection.Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunizationFactors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patientsThe RTS,S vaccine candidate for malaria.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.Canadian Adjuvant Initiative Workshop, March 26-27, 2013--Ottawa, CanadaHighly effective generic adjuvant systems for orphan or poverty-related vaccinesTLR-based immune adjuvants.Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease
P2860
Q21089976-2A849D90-CA5C-47C7-8B37-970868D26729Q24658073-EA75AC2B-8263-4525-A4F5-ACE7AD2D1E06Q26747586-FFF3D69E-67EE-4008-BD98-93D4A925266EQ26752522-572715E4-BD62-46D6-B0C3-8701CCDA1436Q26991640-0C40F46F-B06A-4E1E-A10E-ABCFA697BE3FQ27013956-61E03FB6-9BC8-479C-BDF1-D2C45D21167FQ27305883-75300B42-556F-4AF9-A481-211AECA87262Q27693242-BE115191-014E-470E-B104-54B797D16669Q28072236-87F3B43A-533C-4E83-8B87-4678E127CF5AQ28083679-B68E7062-3425-4EFD-88A3-F2796F467D2CQ28084325-F1DE012A-CD25-4FF6-9C1F-AC1A57B70E37Q28357079-4C2FD4FF-EA6A-4BB0-B675-AC3019344174Q28972540-7E74D6E9-D153-427C-9703-214C03D2A5F4Q30360897-4D2FAADA-24B6-4500-BC5C-1E2BC4E8019AQ30377217-A100D123-D305-4C7C-BA83-AFAFBC227CB3Q30390413-5F149E53-6516-4629-9009-C392BF04D3D7Q30396657-62E443B2-E332-444D-B3D3-6703B0CCA51FQ30397652-941421A7-C573-45C8-9D02-0D535E6EC93EQ30401304-DC96E22A-2353-4ADB-AA0D-344574075A87Q30430552-5992A366-DEA9-4F71-9B80-897388A38263Q33367582-917E1D40-0BAB-4328-9124-BA7FC716A5C1Q33434412-A77BF8FC-AB8F-4D67-A41D-4D7F3B801C02Q33508230-EC3782DB-45A7-47C6-8AA9-5C6EED105E61Q33617905-A2C0537A-870A-4F51-A342-754FF376C05BQ33645835-9B75E446-B51B-4472-9E63-A3A6347719F3Q33835103-54C5405F-39FA-4F3C-87ED-1CBAAD3B33E0Q33862861-437939D5-74EA-44E0-B020-C4930308D439Q33891821-8CB51A06-7CFB-40DA-8BEC-E2578A382F46Q33981953-4836CAF4-11CF-4931-802A-C2432A1B5DF6Q34019854-8145C765-6018-469C-9FB4-FCDBE1B14F08Q34119427-E58388A9-CDBF-45F1-B1A0-0A033F7ADA3AQ34168451-12316609-CDBD-4E21-AB6D-F6936A50EEC4Q34186762-594A0E3A-DFED-49D5-BDE4-1C4102B37540Q34247261-ED5041D3-8245-4F8B-A921-8F8D67C24E30Q34289930-92FFB9CC-794C-42EF-83FB-33AF70370F7EQ34290818-72FC50DB-9E01-447B-B028-61478AF764B2Q34307955-44F8C706-3FC6-4B12-9288-6A8F65AEDA04Q34400322-D484CDF1-CF7A-4E95-848A-3610FF36B2A0Q34484575-0F800089-453E-4155-9AFB-DA33CF30D027Q34506439-0FA94017-3BDA-4824-BAFB-C20602F46AD5
P2860
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@ast
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@en
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@nl
type
label
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@ast
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@en
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@nl
prefLabel
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@ast
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@en
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@nl
P2093
P356
P1476
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.
@en
P2093
Marcelle Van Mechelen
Nathalie Garçon
Patrick Chomez
P304
P356
10.1586/14760584.6.5.723
P577
2007-10-01T00:00:00Z